XML 50 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Loan Payable (Details)
3 Months Ended
Jan. 15, 2021
USD ($)
tranche
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Debt Instrument [Line Items]      
Loan payable (net of discount and issuance costs of $692 and $756, respectively)   $ 15,133,000 $ 15,069,000
Term Loan Member      
Debt Instrument [Line Items]      
Debt Instrument, Face Amount $ 35,000    
Number of tranches | tranche 3    
Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate 715.00%    
Debt Instrument, Basis Spread on Variable Rate 700.00%    
ThersholdIndexRate 15.00%    
Debt Instrument, Periodic Payment, Principal $ 500    
Debt Instrument, Unamortized Discount, Noncurrent 898,000    
Payments of Debt Issuance Costs 95,000    
Interest Expense, Debt   $ 333,000 $ 231,000
Tranch A Term Loan Member      
Debt Instrument [Line Items]      
Debt Instrument, Face Amount 15,000,000    
Tranch B Term Loan Member      
Debt Instrument [Line Items]      
Debt Instrument, Face Amount $ 10,000,000    
Debt Instrument, Covenant Description receipt of at least $50,000 in Series C equity capital, ii) initiation of the Phase 1 combination study of TPST-1495 or monotherapy expansion study, and iii) initiation of Phase 2 trial of TPST-1120 or the 1L Triplet Collaboration study    
Tranch C Term Loan Member      
Debt Instrument [Line Items]      
Debt Instrument, Face Amount $ 10,000